- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Organ Transplant Recipients more prone to Risks of recurrent Multiple Skin Cancers: JAMA
There have been few studies on the chances of developing numerous primary skin malignancies in organ transplant patients (OTRs).
According to a retrospective cohort study, about half of the organ transplant patients (OTRs) who acquired at least one post-transplant skin cancer developed a subsequent skin cancer within two years, and roughly one in twenty developed ten or more skin cancers.
The study was conducted by Mackenzie R. Wehner and team and the findings of the study were published in JAMA Dermatology on 20th October, 2021.
The study was aimed to assess the risks over time and risk factors for OTRs getting (1) any skin cancer after transplant, (2) a second skin cancer after the first post-transplant skin cancer in the data sets used in the study, and (3) 10 or more skin cancers in the data sets used in the study. From 2007 to 2017, data from the Optum deidentified electronic health record data collection (7.7 million patients) and the Truven Health MarketScan insurance claims data set (161 million patients) were utilized in this retrospective cohort analysis. Skin malignancies were recognized using diagnostic plus treatment codes for basal cell carcinoma, squamous cell carcinoma, and melanoma; OTRs were identified using 4 or more organ transplant diagnosis codes. The data was analyzed between January 1, 2007 and December 31, 2017.
In this cohort research, 4.5% to 13.3% of OTRs had at least one skin cancer treatment, according to data from an electronic health record and a claims database. In the data sets, OTRs had a 44.0% to 57.0% probability of a future skin cancer treatment and a 3.7% to 6.6% likelihood of having 10 or more skin cancer treatments at 2 years following an initial post-transplant skin cancer. Treatment options and skin cancer kinds were found to be compatible with clinical expectations (e.g., SCC is treated mostly with destruction) and other published material (the majority of skin cancers in OTRs are SCC, followed by BCCs, followed by melanoma).
In conclusion, the findings of this study suggest that approximately half of OTRs who develop at least one post-transplant skin cancer may develop a subsequent skin cancer within two years, and approximately one in twenty may develop ten or more skin cancers, emphasizing the importance of diligent dermatology follow-up.
Reference:
Wehner MR, Niu J, Wheless L, et al. Risks of Multiple Skin Cancers in Organ Transplant Recipients: A Cohort Study in 2 Administrative Data Sets. JAMA Dermatol. Published online October 20, 2021. doi:10.1001/jamadermatol.2021.4148
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751